Recruiting Advanced Solid Tumors Studies in Austin
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers....
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygo...
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors ha...
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 adminis...
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RĪ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or meta...
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...
About Advanced Solid Tumors Clinical Trials in Austin
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 7 advanced solid tumors clinical trials recruiting participants in Austin, TX. These studies are seeking a combined 1,474 participants. Research is being sponsored by BiOneCure Therapeutics Inc., Servier Bio-Innovation LLC, Terremoto Biosciences Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Austin ā FAQ
Are there advanced solid tumors clinical trials in Austin?
Yes, there are 7 advanced solid tumors clinical trials currently recruiting in Austin, TX. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Austin?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Austin research site will contact you about next steps.
Are clinical trials in Austin free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Austin studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 7 active trials in Austin are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov